Navigation Links
Positive Preclinical Data on Cell Therapy for Spinal Disc Repair Presented at 23rd Annual Meeting of the North American Spine Society

ST. LOUIS, Oct. 16 /PRNewswire/ -- ISTO Technologies, Inc., a privately held orthobiologics company, today announced positive preclinical data related to its NuQu(TM) injectable cell-based therapy for spinal disc repair. The data was presented in Toronto, Canada at the 23rd Annual Meeting of the North American Spine Society. Studies carried out at the University of California San Francisco (UCSF) Department of Orthopedics were designed to investigate potential applications of ISTO's core cell-based platform technology (juvenile cartilage cells) as a non-invasive procedure for treatment of degenerative intervertebral disc. In these pre-clinical studies, the disc nucleus from adult pigs was removed and replaced with juvenile chondrocytes in a protein gel carrier.

"We are encouraged by the results of the UCSF preclinical studies and we believe ISTO's cell-based therapy may offer a breakthrough for early non- surgical intervention for patients suffering from back pain," said Mitchell Seyedin, Ph.D., President & CEO.

"Because the disc environment is only conducive to highly specialized cells, the purpose of this preclinical study was to evaluate whether juvenile cartilage cells can effectively replace and regenerate cartilage in the nucleus," said Jeffrey Lotz, Ph.D., Director of the Orthopaedic Bioengineering Laboratory at UCSF. "We are very encouraged by the fact, that in several animal studies, these cells have shown the ability to generate cartilage in the disc nucleus in a predictable and consistent basis," said Dr. Lotz.

NuQu is being developed as a non-invasive treatment for degenerative disc disease for patients who are suffering from low back pain and have failed to respond to conservative therapy. The economic and social impact of back pain due to disc degeneration places a tremendous burden on patients, the healthcare system and the overall economy. Today, there is no effective treatment for degenerative disc disease.

Disc degeneration, thought to be the major cause of back pain, begins in the nucleus and is accompanied by cell death and tissue destruction. Cartilage regeneration is often called the "holy grail" of the orthopedic industry because of its potential to restore function to damaged joints and spinal discs which otherwise have limited healing potential. Cartilage serves as a "shock absorber", protecting all joints including spinal discs from the wear-and-tear experienced during motion.

ISTO Technologies, Inc. is an orthobiologics company focusing on the development of differentiated products for sport medicine, spinal therapy and trauma. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone.

For additional information, visit ISTO Technologies' website at or contact Scott Gill, Chief Financial Officer, by phone at (314) 995-6049.

SOURCE ISTO Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
2. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
3. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
4. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
5. Kuvan Receives Positive Opinion From CHMP for European Approval
6. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
7. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
8. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
9. Positive SPA Reply From the FDA for TopoTargets Pivotal Trial With Belinostat in PTCL
10. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
11. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
Post Your Comments:
(Date:12/1/2015)... Texas (PRWEB) , ... December ... ... , a leading relationship marketing company specializing in scientifically backed, age-defying products, ... January 2016 issue, which highlights the exponential success and unrivaled opportunities that ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... global meeting this month and Dr. J. Kyle Mathews will join ... includes the new single site hysterectomy. , An experienced urogynecologist, founder of Plano ...
(Date:11/30/2015)... ... ... Global Stem Cells Group announced that its scientific team is in the ... cells. The announcement starts a new phase toward launching the simple, quick system for ... lipoaspirate obtained from liposuction of excess adipose tissue. , Lipoaspirate, contains a large ...
(Date:11/30/2015)... MONTREAL , Dec. 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... that it has joined the American Business Act on Climate ... economy that are standing with the Obama Administration to demonstrate ... for a strong outcome to the COP21 Paris ... . --> Sarnia, Canada . ...
Breaking Biology Technology:
(Date:11/17/2015)... Nov. 17, 2015  Vigilant Solutions announces today that ... Board of Directors. --> ... retiring from the partnership at TPG Capital, one of ... over $140 Billion in revenue.  He founded and led ... the TPG companies, from 1997 to 2013.  In his ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
(Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
Breaking Biology News(10 mins):